Pre-Cert
The HIMSS Media team gives a recap of recent headlines surrounding the FDA, COVID-19 and new digital health software products.
Dr. Yuri Maricich, chief medical officer at Pear Therapeutics, speaks on his company's experience bringing a digital therapeutic product through the regulator's experimental program for health software.
The results to our poll about the FDA program prompt questions about the program's fairness to companies big and small.
The road to FDA clearance for medical devices may change radically in the next year.